HCV Treatment
Managing Side Effects of New Hepatitis C Protease Inhibitors
- Details
- Category: HCV Treatment
- Published on Tuesday, 14 February 2012 00:00
- Written by Liz Highleyman
Adding the recently approved hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) or telaprevir (Incivek) to pegylated interferon plus ribavirin can shorten the course of treatment and increase the likelihood of a cure, but can also lead to more adverse events. Fortunately, side effects are typically mild-to-moderate and usually can be managed without stopping therapy, according to a recent review.
FDA Lifts Hold on Idenix HCV Polymerase Inhibitor IDX184
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 07 February 2012 00:00
- Written by Idenix
The U.S. Food and Drug Administration (FDA) last week gave the go-ahead for further development of Idenix Pharmaceuticals' hepatitis C virus (HCV) nucleotide polymerase inhibitor IDX184. The agency lifted a hold imposed after a few healthy volunteers who received a combination of IDX184 plus another experimental agent, IDX321, in an early clinical trial developed elevated liver enzymes; further analysis indicates that liver toxicity is likely attributable to the second drug.
Achillion, Presidio, Idenix Announce HCV Drug Pipeline Developments
- Details
- Category: HCV Treatment
- Published on Tuesday, 17 January 2012 00:00
- Written by Press Release
Three companies developing direct-acting antiviral agents (
DAAs) for hepatitis C virus (HCV) infection recently announced progress on new experimental drug candidates.
High Rate of Sustained Response with Interferon-Free Daclatasvir + Asunaprevir for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 24 January 2012 00:00
- Written by Liz Highleyman
A dual oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) protease inhibitor asunaprevir (formerly BMS-650032) and HCV NS4A inhibitor daclatasvir (BMS-790052) cleared the virus in one-third of genotype 1 prior null responders to prior interferon-based therapy, and both of those with genotype 1b, according to data published in the January 19, 2012, New England Journal of Medicine.
Pharmasset Halts Testing of HCV Polymerase Inhibitor PSI-938 Due to Liver Problems
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 January 2012 00:00
- Written by Press Release
Pharmasset announced in December that it would change the design of its ongoing QUANTUM trial to discontinue treatment with its hepatitis C virus (HCV) nucleotide polymerase inhibitor PSI-938, after routine safety monitoring revealed liver function abnormalities.
Web Design and Development by